Suly Brea
Family · Boynton Beach, FLNPI 1154056414
Payments from drug & device makers
Across 261 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$665
- AstraZeneca$494
- Merck$390
- E.r. Squibb & Sons, L.L.C.$372
- Boehringer Ingelheim$332
- Amgen$318
- plus $3K from 26 others
What the payments were for
- Food & beverage$5,206100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 22 | $665 |
| AstraZeneca | 26 | $494 |
| Merck | 20 | $390 |
| E.r. Squibb & Sons, L.L.C. | 18 | $372 |
| Boehringer Ingelheim | 15 | $332 |
| Amgen | 22 | $318 |
| Cvrx, Inc. | 27 | $274 |
| Novartis | 12 | $272 |
| Pfizer | 10 | $210 |
| Abbott | 9 | $193 |
| Alnylam Pharmaceuticals Inc. | 9 | $188 |
| United Therapeutics Corporation | 6 | $176 |
| Bridgebio Pharma, Inc. | 7 | $133 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $132 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $96 |
| Abiomed | 5 | $89 |
| Heartflow, Inc. | 2 | $88 |
| Bayer | 4 | $86 |
| Lexicon Pharmaceuticals, Inc. | 4 | $85 |
| Johnson & Johnson | 4 | $70 |
| Medtronic | 3 | $69 |
| Novo Nordisk | 3 | $68 |
| Boston Scientific | 3 | $66 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Agepha Pharma FZ LLC | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $40 |
| Stryker | 1 | $36 |
| Edwards Lifesciences | 1 | $34 |
| Inari Medical, Inc. | 1 | $29 |
| Biotronik Inc. | 1 | $22 |
| ZOLL Circulation Inc | 2 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$126
How this compares
$5,219 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $104,812 |
| EntrestoSacubitril/Valsartan | 27 | $37,590 |
| XareltoRivaroxaban | 28 | $34,655 |
| FarxigaDapagliflozin Propanediol | 14 | $18,490 |
| Repatha SureclickEvolocumab | 14 | $13,143 |
| BrilintaTicagrelor | 14 | $11,122 |
| Repatha SyringeEvolocumab | 11 | $7,853 |
| CorlanorIvabradine Hcl | 13 | $7,622 |
| Rosuvastatin Calcium | 234 | $2,466 |
| Metoprolol Succinate | 174 | $2,344 |
| Atorvastatin Calcium | 167 | $1,719 |
| Valsartan | 45 | $1,125 |
| Ezetimibe | 52 | $1,017 |
| Nifedipine ErNifedipine | 48 | $974 |
| Losartan Potassium | 112 | $950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $210 | $104,81281 claims |
| NovartisEntresto | $272 | $37,59027 claims |
| Johnson & JohnsonXarelto | $70 | $34,65528 claims |
| AstraZenecaFarxiga, Brilinta | $494 | $29,61228 claims |
| AmgenCorlanor | $318 | $7,62213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Boynton Beach
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.